Institute for OneWorld Health
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
The Institute for OneWorld Health is a nonprofit pharmaceutical company founded in 2000 to develop safe, effective, and affordable new medicines for people with infectious diseases in the developing countries.
Drug development efforts
Currently, two drugs are under development a drug to treat Chagas disease in Latin America and a drug to cure visceral leishmaniasis in India. Paromomycin, the drug being developed to treat visceral leishmaniasis, was granted orphan drug status in 2005 by both the FDA and EMEA.[1] Prior to this approval, Phase 3 clinical trials for this indication were conducted in India in 2003—2004. The overall conclusion was that efficacy and side effects were similar to the comparison agent in the trials, amphotericin B, results which in August 2006 led to approval for treatment of visceral leishmaniasis by the Indian government.[2]
Executives
- Dr. Victoria Hale Ph.D., CEO and Chairman of the Board of Directors.
- Dr. Ahvie Herskowitz M.D., COO and Chief Medical Officer.
Major supporters
- Bill & Melinda Gates Foundation[3][4] (the Institute received 96% of its funding from the Foundation as of 2006)[5]
- Amgen, Chiron Corporation, Gap, Lehman Brothers, Pfizer, Vital Spark Foundation, Skoll Foundation[5]
References
- ↑ Radia, Hina (23 May 2005). US FDA and EMEA grant “Orphan Drug” designation for paromomycin injection to treat visceral leishmaniasis. Biospace.com. Archived from the original on 2005-05-24. Retrieved on 2007-07-30. (abstract preserved by National Health Service)
- ↑ Sundar, Shyam; T.K. Jha, Chandreshwar P. Thakur, Prabhat K. Sinha and Sujit K. Bhattacharya (21 June 2007). "Injectable Paromomycin for Visceral Leishmaniasis in India". New England Journal of Medicine 356 (25): 2571–2581. PMID 17582067. Retrieved on 2007-07-30.
- ↑ Bill & Melinda Gates Foundation (13 July 2004). Institute for OneWorld Health Receives Gates Foundation Grant To Fund Development of Malaria Vaccine. Press release. Retrieved on 2007-07-30.
- ↑ Bill & Melinda Gates Foundation (14 April 2005). Institute for OneWorld Health Receives Grant To Lay Foundation for Next Steps in Control of Deadly Infectious Disease. Press release. Retrieved on 2007-07-30.
- ↑ 5.0 5.1 Shears, Angela Rickabaugh. "Curing the Third World", Philanthropy Magazine, Philanthropy Roundtable, 25 September 2006. Retrieved on 2007-07-31.
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
